Verdot announces collaboration with Moderna on Intismeran, a personalized mRNA-based cancer therapy.

Located at Biopôle Clermont-Limagne in Saint-Beauzire, France, VERDOT, a specialist in purification technologies for the biopharmaceutical industry, announces its collaboration with Moderna, a global leader in biotechnology. The two companies are working together on the design and manufacture of advanced manufacturing units for Intismeran, a personalized mRNA-based cancer therapy currently under development.

The equipment will be deployed at Moderna’s site in Marlborough, Massachusetts, USA. It will help expand the manufacturing capabilities required for this innovative approach to immuno-oncology, particularly in the treatment of melanoma.

This collaboration highlights one of VERDOT’s highly specialized areas of expertise: the design of miniaturized fluidic architectures and the manufacture of small-scale systems that meet Good Manufacturing Practice (GMP) requirements.

In the field of mRNA therapies and personalized medicines, mastering small-scale manufacturing processes is a major challenge. Key priorities include reducing operating costs and equipment footprint, while minimizing manual intervention through compact equipment, streamlined operations and increased automation.

These developments must nevertheless meet particularly stringent requirements in terms of precision, containment, reproducibility and regulatory compliance.

This collaboration with Moderna demonstrates VERDOT’s ability to leverage its technological expertise in major international industrial projects, supporting the development of next-generation therapies.

Following the recent inauguration of its new headquarters and production facility at the Biopôle Clermont-Limagne site in Saint-Beauzire, the company is further strengthening its resources and support capabilities. This new Centre of Excellence will enable VERDOT to continue developing advanced technologies and address the growing needs of its customers in a rapidly evolving biopharmaceutical industry.